The preceding modules established the pharmacological foundations of lipid-lowering therapy — lipoprotein biology, statin mechanisms and evidence, and the role of non-statin agents. This capstone module applies that knowledge to the clinical contexts where lipid management decisions are most complex and consequential: familial hypercholesterolemia, the post-acute coronary syndrome patient, heart failure, severe hypertriglyceridemia with pancreatitis risk, combined dyslipidemia in diabetes, and the elderly patient in whom the benefit-risk calculus is genuinely uncertain. Each of these populations presents challenges that cannot be resolved by rote application of guidelines — they require mechanistic understanding, familiarity with the relevant trials, and the judgment to individualize therapy within an evidence-based framework. The module also addresses deprescribing as a clinically appropriate endpoint in selected elderly patients — a concept that has gained traction as primary prevention data in older populations have matured.
Familial hypercholesterolemia (FH) is a monogenic disorder of LDL metabolism characterized by markedly elevated low-density lipoprotein cholesterol (LDL-C) from birth and accelerated premature atherosclerotic cardiovascular disease (ASCVD). The most common genetic causes are autosomal dominant loss-of-function mutations in the LDL receptor gene (LDL receptor (LDLR), accounting for approximately 85–90% of genetically confirmed FH), gain-of-function mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9) (approximately 1–3%), and loss-of-function mutations in apolipoprotein B (apolipoprotein B gene (APOB), approximately 5–10%), which impairs LDLR-LDL binding.1 Heterozygous FH (HeFH) affects approximately 1 in 250 individuals globally — making it the most common monogenic cardiovascular disease — and is characterized by LDL-C typically 190–400 mg/dL untreated. Homozygous FH (HoFH) affects approximately 1 in 300,000–1,000,000 individuals, with LDL-C typically 400–1,000 mg/dL and frequently presenting with cutaneous xanthomas, corneal arcus, and aortic stenosis in childhood or early adulthood.1 Both conditions are substantially underdiagnosed and undertreated in clinical practice.
The diagnosis of HeFH can be made clinically using validated scoring systems. The Dutch Lipid Clinic Network (DLCN) criteria incorporate: LDL-C level, personal history of premature ASCVD (first-degree male <55 years, female <60 years), family history of premature ASCVD or elevated cholesterol, and physical examination findings (tendon xanthoma, corneal arcus before age 45).1 A DLCN score ≥6 is "probable FH"; ≥8 is "definite FH." A practical clinical trigger for FH evaluation: untreated LDL-C ≥190 mg/dL in an adult, or any child with LDL-C ≥160 mg/dL. Genetic testing confirms the diagnosis and enables cascade screening of first-degree relatives — the single most cost-effective intervention in FH management, as each identified mutation carrier can be treated before ASCVD events occur.1 However, genetic testing is negative in approximately 20–40% of clinically diagnosed FH patients, reflecting the large number of rare variants not captured by standard panels; a negative genetic test does not exclude clinical FH.
All patients with HeFH require high-intensity statin therapy initiated as early as possible — from age 8–10 years in affected children, per guidelines.1 The treatment target for adults with HeFH without established ASCVD is LDL-C <100 mg/dL (ACC/AHA) or <100 mg/dL in moderate risk, <70 mg/dL in high risk (ESC/European Atherosclerosis Society (EAS)); for HeFH patients with established ASCVD, the target is <70 mg/dL (ACC/AHA) or <55 mg/dL (ESC/EAS).7 Most HeFH patients require combination therapy: high-intensity statin plus ezetimibe typically achieves 60–65% LDL-C reduction from baseline, which is often insufficient to meet targets when starting LDL-C is 250–350 mg/dL. PCSK9 inhibitors (evolocumab, alirocumab) reduce LDL-C by an additional 55–70% on background statin plus ezetimibe and are the standard third agent in HeFH patients not at target on dual therapy.1 The FDA approved evolocumab specifically for HeFH in 2015.
HoFH patients carry two mutant LDLR alleles and have severely reduced or absent functional LDLR activity. Because statins and ezetimibe work primarily by upregulating LDLR (statins via sterol regulatory element-binding protein (SREBP)-2; ezetimibe indirectly), their efficacy in HoFH is markedly attenuated compared to HeFH — LDL-C reductions of only 10–25% are typical.1 PCSK9 inhibitors similarly depend on functional LDLR for their effect (preventing PCSK9-mediated degradation of receptors that must be present to clear LDL); in true receptor-negative HoFH, PCSK9 inhibitors are largely ineffective. Two agents specifically approved for HoFH address LDLR-independent pathways: Lomitapide (Juxtapid) is a microsomal triglyceride transfer protein (MTP) inhibitor that blocks the assembly of apolipoprotein B (apoB)-containing lipoproteins (very low-density lipoprotein (VLDL), chylomicrons) in hepatocytes and enterocytes, reducing lipoprotein secretion independent of LDLR.2 At doses of 5–60 mg/day, lomitapide reduces LDL-C by approximately 40–50% in HoFH patients as an add-on to other therapies.
Adverse effects include hepatic steatosis (which is dose-dependent and reversible with dose reduction), gastrointestinal disturbances (diarrhea, nausea, abdominal pain — substantially attenuated by a very low-fat diet and gradual dose titration), and elevation of liver transaminases. It carries a boxed warning for hepatotoxicity and is available only through a Risk Evaluation and Mitigation Strategy (REMS) program.2
Evinacumab (Evkeeza) is a fully human monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3), an endogenous inhibitor of both lipoprotein lipase (LPL) and endothelial lipase. Inhibiting ANGPTL3 enhances triglyceride (TG)-rich lipoprotein clearance and reduces hepatic VLDL production through an LDLR-independent mechanism, thereby lowering LDL-C even in receptor-negative HoFH patients.2 Evinacumab 15 mg/kg IV every 4 weeks reduces LDL-C by approximately 47% in HoFH on maximally tolerated background therapy, including in patients with no residual LDLR function. FDA approval was granted in 2021 for adults and adolescents ≥12 years with HoFH. Adverse effects include nasopharyngitis, influenza-like illness, dizziness, and rhinorrhea; the IV administration route is a practical consideration.2 Evinacumab is also being investigated in other severe dyslipidemias including refractory HeFH and hypertriglyceridemia. Lipoprotein apheresis remains an important adjunct in HoFH and in severe refractory HeFH with recurrent ASCVD events despite maximal drug therapy. It reduces LDL-C acutely by 50–75% per session (every 1–2 weeks), but rebound elevation occurs between sessions and the time-averaged LDL-C reduction is approximately 30–40%.1
The post-acute coronary syndrome (ACS) period represents the highest-risk window for recurrent atherosclerotic cardiovascular disease (ASCVD) events and the greatest opportunity for pharmacological risk modification. High-intensity statin therapy should be initiated in all ACS patients regardless of low-density lipoprotein cholesterol (LDL-C) level at presentation — the absolute benefit is proportional to the high baseline event rate, and the pleiotropic effects of early statin therapy (plaque stabilization, endothelial function improvement, anti-inflammatory effects) contribute to early event reduction that precedes significant LDL-C lowering.3 PROVE IT–Thrombolysis in Myocardial Infarction (TIMI) 22 trial (PROVE IT)–TIMI 22 (2004) demonstrated that initiating atorvastatin 80 mg within 10 days of ACS reduced events by 16% vs. pravastatin 40 mg at 30 days, establishing high-intensity statin as the post-ACS standard.3 If the patient is already on a statin at presentation, the statin should be continued or intensified — never discontinued — in the peri-ACS period.
Under the 2018 ACC/AHA guideline, the LDL-C goal for very high-risk secondary prevention patients — including post-ACS — is <70 mg/dL, with a Class IIa recommendation to add ezetimibe if this target is not achieved on maximally tolerated statin, and a Class IIa recommendation to add a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor if the target remains unmet on statin plus ezetimibe.7 The 2019 ESC/EAS guideline targets LDL-C <55 mg/dL with ≥50% reduction from baseline for very high-risk patients, and <40 mg/dL for "extreme risk" patients (recurrent ASCVD events within 2 years despite maximally tolerated therapy).7 The ODYSSEY OUTCOMES trial (ODYSSEY OUTCOMES) trial is especially relevant here: it enrolled ACS patients within 1–12 months of the qualifying event and demonstrated that alirocumab added to maximally tolerated statin reduced major cardiovascular events by 15% and all-cause mortality by 15%.4 The greatest absolute benefit was observed in patients with baseline LDL-C ≥100 mg/dL, making early PCSK9 inhibitor initiation — without first trying ezetimibe — clinically justifiable in this high-LDL-C post-ACS subgroup.
A fasting lipid panel should be obtained within 24–72 hours of ACS presentation (before the acute phase dilution of LDL-C becomes significant, as acute-phase reactants transiently lower LDL-C by 30–40% in the first days after myocardial infarction (MI)). This pre-treatment lipid panel establishes the true baseline LDL-C, which is essential for calculating percentage reduction targets and determining whether add-on therapy will likely be needed. High-intensity statin should be initiated at presentation without waiting for lipid results. A follow-up lipid panel at 4–8 weeks post-discharge guides add-on therapy decisions. In practice, many post-ACS patients who present with LDL-C ≥100 mg/dL will not reach <55 mg/dL (ESC target) or even <70 mg/dL (ACC target) on statin alone, and combination therapy planning should begin at the first post-discharge visit.3
The post-acute coronary syndrome lipid management decision process follows a structured sequence that integrates baseline lipid assessment, statin optimization, and systematic add-on therapy escalation. This algorithm reflects the combined recommendations of the 2018 American College of Cardiology/American Heart Association and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines, adapted for clinical practice.
Step 1 — At presentation: Obtain fasting lipid panel within 24 to 72 hours. Initiate high-intensity statin immediately (atorvastatin 40 to 80 milligrams or rosuvastatin 20 to 40 milligrams) regardless of the baseline low-density lipoprotein cholesterol result. If the patient is already on a statin, continue it at the current dose or intensify — never discontinue in the peri-acute coronary syndrome period. Document the baseline low-density lipoprotein cholesterol as the reference point for future percentage reduction calculations.
Step 2 — At 4 to 8 weeks post-discharge: Repeat fasting lipid panel. Assess low-density lipoprotein cholesterol response. If low-density lipoprotein cholesterol is below 55 milligrams per deciliter (European Society of Cardiology target for very high risk) or below 70 milligrams per deciliter with at least 50 percent reduction from baseline (European Society of Cardiology) — the patient is at target; continue current therapy with annual monitoring. If low-density lipoprotein cholesterol remains above target on maximally tolerated high-intensity statin: proceed to Step 3.
Step 3 — Add ezetimibe 10 milligrams daily. This is the standard next step per both American College of Cardiology/American Heart Association and European Society of Cardiology guidelines — inexpensive, well-tolerated, provides an additional 18 to 24 percent low-density lipoprotein cholesterol reduction, and has cardiovascular outcomes evidence from the Improved Reduction of Outcomes: Vytorin Efficacy International Trial. Recheck lipid panel in 4 to 6 weeks. If low-density lipoprotein cholesterol is now at target — continue; annual monitoring. If low-density lipoprotein cholesterol remains above target on statin plus ezetimibe: proceed to Step 4. Exception: patients with baseline low-density lipoprotein cholesterol at or above 100 milligrams per deciliter may reasonably skip ezetimibe and proceed directly to Step 4 given the demonstrated benefit of early proprotein convertase subtilisin/kexin type 9 inhibitor initiation in this subgroup from ODYSSEY OUTCOMES subgroup analyses.
Step 4 — Add a proprotein convertase subtilisin/kexin type 9 inhibitor (evolocumab 140 milligrams every 2 weeks or 420 milligrams monthly; alirocumab 75 to 150 milligrams every 2 weeks; or inclisiran 284 milligrams on day 1, month 3, then every 6 months). At this step, prior authorization documentation should be prepared simultaneously with the prescription — documenting confirmed atherosclerotic cardiovascular disease diagnosis, maximally tolerated statin use, ezetimibe use or documented intolerance, and low-density lipoprotein cholesterol above target on dual therapy. If prior authorization is denied, appeal with the clinical rationale for medical necessity including the patient's post-acute coronary syndrome status and specific low-density lipoprotein cholesterol values. Recheck lipid panel in 4 to 8 weeks. Most patients will reach target; if not, verify medication adherence before considering further escalation.
Step 5 — Recurrent events or extreme risk: For patients with a second atherosclerotic cardiovascular disease event within 2 years despite maximally tolerated therapy — the European Society of Cardiology extreme risk category with a low-density lipoprotein cholesterol target below 40 milligrams per deciliter — the full triple combination of high-intensity statin plus ezetimibe plus proprotein convertase subtilisin/kexin type 9 inhibitor is appropriate, and consideration should be given to whether inclisiran (with its stable twice-yearly dosing) might improve adherence compared to the monoclonal antibody self-injection schedule in this high-priority group.
Heart failure (HF) is associated with markedly elevated atherosclerotic cardiovascular disease (ASCVD) risk — the majority of HF with reduced ejection fraction (HFrEF) is of ischemic etiology, and even non-ischemic HF carries elevated cardiovascular mortality. Observational studies and subgroup analyses from statin trials consistently showed reduced mortality in HF patients on statins, generating the hypothesis that statins might reduce HF progression or mortality through pleiotropic mechanisms — reduced inflammatory cytokine production, improved endothelial function, reduced oxidative stress, and anti-arrhythmic effects.5
Two large randomized controlled trials were specifically designed to test statin therapy in chronic HF and produced concordantly negative results: CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure, 2007) enrolled 5,011 patients ≥60 years with ischemic HFrEF (left ventricular ejection fraction (LVEF) ≤40%) and NYHA class II–IV symptoms and randomized them to rosuvastatin 10 mg or placebo.5 Despite reducing low-density lipoprotein cholesterol (LDL-C) by 45% and CRP by 37%, rosuvastatin did not reduce the primary endpoint of cardiovascular death, non-fatal myocardial infarction (MI), or non-fatal stroke (HR 0.92; p=0.12). There was a significant reduction in hospitalizations for cardiovascular causes as a secondary endpoint, but no mortality benefit. GISSI-HF (2008) enrolled 4,574 patients with chronic HF of any etiology (NYHA class II–IV) and randomized them to rosuvastatin 10 mg or placebo.5 The primary endpoints were all-cause mortality and the composite of all-cause mortality or cardiovascular hospitalization. Neither primary endpoint was significantly reduced by rosuvastatin. A secondary analysis showed a trend toward reduced cardiovascular hospitalizations, consistent with CORONA.
The failure of statins to reduce mortality in chronic HF — despite their robust benefit in other ASCVD contexts — is termed the "statin paradox in HF." Several mechanisms have been proposed: (1) In advanced HF, the predominant mode of death shifts from atherothrombotic events toward sudden cardiac death (from arrhythmia) and pump failure — causes not prevented by LDL-C lowering. (2) Very low LDL-C in advanced HF may be a marker of malnutrition and cachexia rather than a modifiable risk factor — the J-curve relationship between cholesterol and survival in severe HF may reflect reverse causation. (3) Advanced HF patients often have low circulating lipoproteins due to reduced hepatic synthesis; statins may further reduce an already-depleted substrate.5
The current clinical approach: (1) In patients with HF of ischemic etiology who have established ASCVD, statin therapy for ASCVD secondary prevention should be continued — the established secondary prevention benefit applies and the HF does not negate it. (2) Initiating statin therapy de novo in patients with HF solely for HF outcomes (without concurrent ASCVD indication) is not supported by evidence and is not currently recommended by HF guidelines (ACC/AHA HF guidelines, ESC HF guidelines).5 (3) In patients with stable HF receiving a statin who are doing well tolerating it, there is no evidence-based reason to discontinue — observational data consistently show associations between statin use and improved outcomes in HF that are likely driven by patient selection (healthier patients more likely to be on statins) but create no basis for active discontinuation.
The clinical approach to hypertriglyceridemia depends on the absolute triglyceride (TG) level, as the therapeutic goals differ at different TG thresholds: Borderline-high TG (150–199 mg/dL): Lifestyle modification is the primary intervention — dietary refinement (reduction of refined carbohydrates, sugar, alcohol), weight loss, aerobic exercise, and optimization of glucose and thyroid status. Pharmacological therapy is not routinely indicated at this level unless global atherosclerotic cardiovascular disease (ASCVD) risk is high and icosapentaenoic acid ethyl ester (IPE) criteria are met.6 High TG (200–499 mg/dL): This range encompasses the Reduction of Cardiovascular Events with Icosapentaenoic Acid-Intervention Trial (REDUCE-IT) eligibility window (135–499 mg/dL). For patients with established ASCVD or diabetes on statin therapy in this range, IPE 4 g/day is indicated (Class IIa, ACC/AHA) for ASCVD event reduction.6 Fibrates do not reduce cardiovascular events in this range (PROMINENT). Lifestyle optimization remains essential.
Very high TG (500–999 mg/dL): Pancreatitis risk becomes significant. First-line pharmacological therapy is fenofibrate; lifestyle modification (very low-fat diet, alcohol cessation, glucose optimization) must be concurrent. IPE may be added once TG falls below 500 mg/dL (outside REDUCE-IT eligibility ceiling). Secondary causes of hypertriglyceridemia should be aggressively addressed: uncontrolled diabetes, hypothyroidism, alcohol excess, nephrotic syndrome, medications (corticosteroids, beta-blockers, thiazides, oral estrogens, antiretrovirals, atypical antipsychotics).6 Severe/very severe TG (≥1,000 mg/dL): Acute pancreatitis risk is high. Hospitalization and immediate dietary fat restriction (<15% of calories) are indicated. Pharmacological TG reduction with fenofibrate and insulin infusion (in patients with diabetic hypertriglyceridemia — insulin activates lipoprotein lipase (LPL), the primary enzyme for TG hydrolysis) should be initiated urgently. Plasmapheresis is reserved for TG >2,000–3,000 mg/dL or when organ-threatening pancreatitis is present or imminent. Novel agents including volanesorsen (an apoC-III antisense oligonucleotide, FDA-approved for familial chylomicronemia syndrome in adults, the most severe monogenic form of hypertriglyceridemia) target very low-density lipoprotein (VLDL) production at the mRNA level and are discussed further below.6
Apolipoprotein C-III (apoC-III) is a key regulator of triglyceride metabolism — it inhibits LPL, inhibits hepatic clearance of TG-rich lipoproteins via LRP1, and stimulates hepatic VLDL secretion. Loss-of-function mutations in apolipoprotein C-III gene (APOC3) produce very low TG levels and reduced ASCVD risk (confirmed by Mendelian randomization), validating apoC-III as a pharmacological target.6 Volanesorsen (an antisense oligonucleotide targeting apoC-III mRNA) reduces TG by 70–80% in familial chylomicronemia syndrome and by approximately 50–60% in hypertriglyceridemia with elevated apoC-III. It is FDA-approved (2023) for adults with familial chylomicronemia syndrome and is under investigation for broader hypertriglyceridemia indications. Olezarsen (a GalNAc-conjugated antisense oligonucleotide with hepatocyte-targeted delivery) is in phase 3 trials (BRIDGE-TIMI 73a) with favorable phase 2 data showing approximately 60% TG reduction with monthly subcutaneous dosing.6
Type 2 diabetes produces a characteristic dyslipidemia driven by insulin resistance and relative insulin deficiency: elevated triglycerides (TG) (from increased hepatic very low-density lipoprotein (VLDL) secretion and reduced lipoprotein lipase (LPL) activity), low high-density lipoprotein cholesterol (HDL-C) (accelerated HDL catabolism driven by elevated TG and CETP activity), and a predominance of small, dense LDL particles (which are more atherogenic per particle than large, buoyant LDL). Measured low-density lipoprotein cholesterol (LDL-C) may be normal or only modestly elevated, systematically underestimating atherogenic particle burden — making apolipoprotein B (apoB) and non-HDL-C more relevant treatment targets than LDL-C alone in this population.7 The combination of hyperglycemia, dyslipidemia, hypertension, inflammation, and endothelial dysfunction in diabetes produces cardiovascular risk substantially exceeding that predicted by any single risk factor, which is why diabetic patients are treated as a higher-risk group than their LDL-C level alone would suggest.
Statins are the cornerstone of lipid management in diabetes. All patients with type 2 diabetes aged 40–75 should receive at least moderate-intensity statin therapy (ACC/AHA Group 3 recommendation), with high-intensity statin for those with 10-year atherosclerotic cardiovascular disease (ASCVD) risk ≥10% or established ASCVD.7 The statin-associated new-onset diabetes risk (discussed in LD-03) is not a contraindication in patients who already have diabetes. The Heart Protection Study demonstrated equivalent relative risk reductions in diabetic patients without prior CVD as in patients with established CAD, firmly establishing the benefit of statin therapy as a primary prevention strategy in diabetes.
In patients with diabetes at ASCVD risk despite statin therapy, the management strategy proceeds as follows: (1) Achieve LDL-C and apoB targets with statin plus ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor if needed. (2) For patients with TG 135–499 mg/dL on statin — consider icosapentaenoic acid ethyl ester (IPE) 4 g/day (the Reduction of Cardiovascular Events with Icosapentaenoic Acid-Intervention Trial (REDUCE-IT), which enrolled 57% diabetic patients, demonstrated consistent benefit in this subgroup). (3) For very high TG (≥500 mg/dL) — fenofibrate for pancreatitis prevention with concurrent glycemic optimization. (4) Glycemic control itself is a TG-lowering intervention: glucagon-like peptide-1 (GLP-1) receptor agonists (semaglutide, liraglutide) and SGLT-2 inhibitors (empagliflozin, dapagliflozin) reduce TG by 10–20% through improved insulin sensitivity and reduced hepatic lipogenesis, and their established cardiovascular outcome benefits in diabetes are partially mediated through lipid as well as non-lipid mechanisms.7
Given the frequent discordance between LDL-C and atherogenic particle burden in the diabetic dyslipidemia phenotype, non-HDL-C and apoB should be routinely measured and used as co-primary treatment targets. The ACC/AHA guideline identifies non-HDL-C ≥130 mg/dL as an ASCVD risk enhancer; ESC/EAS guidelines formally incorporate apoB <65–80 mg/dL as a co-primary target depending on risk tier. In a diabetic patient with LDL-C at apparent target (e.g., 68 mg/dL) but elevated non-HDL-C (e.g., 115 mg/dL) and apoB (e.g., 90 mg/dL), additional therapy intensification — particularly to address TG-rich remnant particles — is clinically appropriate despite the "normal" LDL-C.7
As discussed in LD-03, the randomized controlled trial evidence for statin therapy in patients ≥75 years is more limited than in younger populations. For secondary prevention — patients ≥75 years with established atherosclerotic cardiovascular disease (ASCVD) — extrapolation from trial data supports continuation of high-intensity statin therapy, as absolute ASCVD risk (and therefore absolute treatment benefit) is highest in this population. The ACC/AHA and ESC guidelines both endorse statin therapy for secondary prevention in older adults without an upper age cutoff, with a recommendation for shared decision-making regarding high- vs. moderate-intensity therapy.8 For primary prevention in patients ≥75 years, the evidence is weaker: the STAREE trial (rosuvastatin 40 mg vs. placebo in adults ≥70 years without established CVD or diabetes) found no significant reduction in the primary composite of disability-free survival — a result that introduced meaningful uncertainty about the primary prevention benefit of high-intensity statin in this age group.8
Older patients present several pharmacokinetic challenges for statin prescribing: reduced hepatic CYP3A4 (cytochrome P450 3A4) activity (increases lipophilic statin exposure), reduced renal clearance (increases rosuvastatin exposure), reduced serum albumin (increases free drug fraction), lower muscle mass and body weight (increases SAMS risk per unit dose), and higher polypharmacy burden (increases CYP interaction probability).8 Practical implications: moderate-intensity statin is the preferred starting point in primary prevention elderly patients; high-intensity statin in secondary prevention should be balanced against tolerability; rosuvastatin dose capping at 20 mg (rather than 40 mg) is reasonable in frail elderly patients.
Deprescribing of statins is an evidence-supported clinical option in selected elderly patients — particularly those with limited life expectancy, advanced frailty, significant polypharmacy, or terminal illness where the long-term cardiovascular benefit is unlikely to be realized within the patient's expected lifespan.8 The OPTIMIZE trial (2021), a cluster-randomized trial of statin discontinuation in patients ≥75 years with limited life expectancy (≤2 years by clinical estimate) on primary prevention statins, demonstrated that discontinuation was safe, reduced pill burden, and improved quality of life measures without significant excess cardiovascular events over 12 months follow-up.8 The LEBRAS trial and other observational deprescribing studies have similarly shown that statin discontinuation in patients ≥80 years on primary prevention does not produce an excess of major cardiovascular events within a 1–2 year window, though longer-term follow-up data are limited.
Deprescribing is not appropriate in secondary prevention patients with established ASCVD and reasonable life expectancy — the continued risk reduction benefit in this group is well-established. The shared decision-making framework for statin deprescribing incorporates: (1) indication (primary vs. secondary prevention); (2) estimated life expectancy vs. time-to-benefit horizon of statin therapy (estimated at approximately 2–5 years); (3) frailty and functional status; (4) patient preferences and values regarding pill burden, medication cost, and cardiovascular risk tolerance; and (5) current statin tolerability.8
Chronic kidney disease produces a distinctive dyslipidemia pattern that differs from the typical hypercholesterolemia of the general population and has important implications for treatment selection. The characteristic lipid profile in chronic kidney disease includes: elevated triglycerides (impaired lipoprotein lipase activity and reduced very low-density lipoprotein clearance); reduced high-density lipoprotein cholesterol (accelerated high-density lipoprotein catabolism); relatively normal or modestly elevated total and low-density lipoprotein cholesterol in most stages, but a predominance of small dense low-density lipoprotein particles that are more atherogenic per unit of measured low-density lipoprotein cholesterol; and elevated lipoprotein(a) and apolipoprotein B-containing remnant particles. The net result is a substantially elevated atherosclerotic cardiovascular disease risk at any given low-density lipoprotein cholesterol level, making chronic kidney disease one of the strongest independent cardiovascular risk enhancers recognized in current guidelines.
Estimated glomerular filtration rate below 60 milliliters per minute per 1.73 square meters (stages G3 to G5) and albuminuria above 30 milligrams per gram creatinine are both independently associated with increased atherosclerotic cardiovascular disease risk, and their combination produces multiplicative rather than additive risk elevation. Patients with chronic kidney disease who also have diabetes or hypertension face a further compounded cardiovascular risk burden. The Kidney Disease: Improving Global Outcomes guidelines recommend statin therapy in all adults with chronic kidney disease (not on dialysis) aged 50 and above, and in adults aged 18 to 49 with one or more additional cardiovascular risk factors including diabetes, prior atherosclerotic cardiovascular disease event, estimated glomerular filtration rate below 30 milliliters per minute per 1.73 square meters, or known duration of chronic kidney disease above 10 years.
The Study of Heart and Renal Protection (SHARP) trial is the definitive evidence base for lipid-lowering therapy in chronic kidney disease. SHARP enrolled 9,270 patients with chronic kidney disease (approximately one-third on dialysis at baseline) and randomized them to simvastatin 20 milligrams plus ezetimibe 10 milligrams versus placebo. The primary composite endpoint of atherosclerotic events (non-fatal myocardial infarction, coronary death, non-hemorrhagic stroke, or arterial revascularization) was reduced by 17 percent relative risk reduction (11.3 percent versus 13.4 percent absolute event rates) over a median of 4.9 years.9 Low-density lipoprotein cholesterol was reduced by approximately 43 percent from baseline. SHARP demonstrated that the statin plus ezetimibe combination was safe in chronic kidney disease — including dialysis patients — and did not accelerate kidney disease progression.
The trial also confirmed that ezetimibe contributes meaningfully to low-density lipoprotein cholesterol lowering in chronic kidney disease patients, where hepatic statin metabolism may be preserved but intestinal cholesterol absorption (the ezetimibe target) remains a significant contributor to circulating low-density lipoprotein cholesterol. A key finding from the dialysis subgroup was that lipid lowering did not reduce atherosclerotic events in prevalent dialysis patients, consistent with the prior neutral AURORA and Deutsche Diabetes Dialyse Studie (4D) trials — suggesting that in end-stage kidney disease on dialysis, the dominant mechanism of cardiovascular death may be uremic cardiomyopathy and sudden cardiac death rather than atherosclerotic plaque rupture, for which lipid lowering has limited efficacy.
Statin pharmacokinetics in chronic kidney disease require careful consideration because impaired renal clearance increases plasma exposure of renally excreted statins. Rosuvastatin undergoes proportionally greater renal elimination than other statins — approximately 28 percent is excreted unchanged in urine — and plasma concentrations increase significantly in severe chronic kidney disease (estimated glomerular filtration rate below 30 milliliters per minute per 1.73 square meters). The rosuvastatin prescribing label recommends against doses above 10 milligrams per day in severe chronic kidney disease and end-stage kidney disease, and starting at 5 milligrams per day in this population. Atorvastatin undergoes minimal renal excretion (less than 2 percent unchanged in urine) and does not require dose adjustment for chronic kidney disease — it is generally the preferred high-intensity statin in the chronic kidney disease population. Pravastatin has intermediate renal excretion and requires modest dose reduction in severe chronic kidney disease. Simvastatin and lovastatin are primarily hepatically metabolized with minimal renal excretion; dose adjustments for chronic kidney disease per se are not required, though the statin-fibrate interaction risk is heightened in chronic kidney disease where fibrate excretion is also impaired.
Ezetimibe requires no dose adjustment in chronic kidney disease and is generally well tolerated across all stages. It is an attractive add-on agent in chronic kidney disease patients not at low-density lipoprotein cholesterol target on statin alone, as demonstrated in SHARP. Proprotein convertase subtilisin/kexin type 9 inhibitors do not require dose adjustment for chronic kidney disease and have been studied in chronic kidney disease populations within the major cardiovascular outcomes trials — Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk and ODYSSEY OUTCOMES both enrolled patients with chronic kidney disease, and the relative risk reductions were consistent with the overall trial populations.
Fenofibrate should be used with caution in chronic kidney disease because it produces a reversible increase in serum creatinine through inhibition of creatinine tubular secretion — not a marker of nephrotoxicity, but a clinically confusing finding that can trigger unnecessary statin or medication changes. Of greater clinical concern, fenofibrate's primary excretion route is renal, and drug accumulation in severe chronic kidney disease substantially increases the risk of myopathy. The prescribing label recommends avoiding fenofibrate when estimated glomerular filtration rate falls below 30 milliliters per minute per 1.73 square meters and using reduced doses when estimated glomerular filtration rate is between 30 and 60 milliliters per minute per 1.73 square meters. Gemfibrozil carries the same concerns and additionally has the statin interaction risk — it should generally be avoided in chronic kidney disease patients on statin therapy.
Renal transplant recipients develop dyslipidemia driven by the same immunosuppressive medications that affect cardiac transplant recipients — calcineurin inhibitor-mediated dyslipidemia, corticosteroid effects, and mTOR inhibitor hypertriglyceridemia. The Assessment of Lescol in Renal Transplantation trial demonstrated that fluvastatin 40 to 80 milligrams reduced cardiac death and non-fatal myocardial infarction by 35 percent in renal transplant recipients over 5 to 6 years, providing specific outcomes evidence in this population. Given the cyclosporine interaction profile, pravastatin and fluvastatin are the most commonly used statins in renal transplant recipients on cyclosporine-based regimens; atorvastatin at reduced doses (10 to 20 milligrams) is an alternative in tacrolimus-based regimens with monitoring.
Nordestgaard BG, Chapman MJ, Humphries SE, et al; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J. 2013;34(45):3478–3490
doi:10.1093/eurheartj/eht273Cuchel M, Bruckert E, Ginsberg HN, et al; European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. Eur Heart J. 2014;35(32):2146–2157
doi:10.1093/eurheartj/ehu274Cannon CP, Braunwald E, McCabe CH, et al; PROVE IT–TIMI 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–1504
doi:10.1056/NEJMoa040583Schwartz GG, Steg PG, Szarek M, et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107
doi:10.1056/NEJMoa1801174Kjekshus J, Apetrei E, Barrios V, et al; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248–2261
doi:10.1056/NEJMoa0706201Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies. Eur Heart J. 2021;42(47):4791–4806
doi:10.1093/eurheartj/ehab551Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111–188
doi:10.1093/eurheartj/ehz455Giral P, Neumann A, Weill A, Coste J. Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. Eur Heart J. 2019;40(43):3516–3525
doi:10.1093/eurheartj/ehz458Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285–e350
doi:10.1016/j.jacc.2018.11.003Bhatt DL, Steg PG, Miller M, et al; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22
doi:10.1056/NEJMoa1812792Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330–343
doi:10.1016/j.jacc.2018.04.061